Viewing Study NCT00050427



Ignite Creation Date: 2024-05-05 @ 11:29 AM
Last Modification Date: 2024-10-26 @ 9:08 AM
Study NCT ID: NCT00050427
Status: COMPLETED
Last Update Posted: 2011-04-28
First Post: 2002-12-09

Brief Title: A Study of ET-743 Trabectedin in Patients With Advanced Breast Cancer
Sponsor: Johnson Johnson Pharmaceutical Research Development LLC
Organization: Johnson Johnson Pharmaceutical Research Development LLC

Study Overview

Official Title: A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer
Status: COMPLETED
Status Verified Date: 2011-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with advanced breast cancer
Detailed Description: Patients will be enrolled in the study after all study specific-entry criteria are met and informed consent is obtained Patients will be required to attend regular clinic visits to receive study medication and have their status monitored Patients will also be required to have radiologic tumor assessments performed at multiple times throughout the study A detailed explanation can be provided by the study physician Investigator conducting this study Trabectedin 580 mcgm2 once weekly for 3 consecutive weeks Treatment A or 1300 mcgm2 once every 21 days Treatment B will be given to patients as a 3-hour intravenous iv infusion via a central venous catheter which is a tube placed into a large vein that is used to administer medications All patients will be given dexamethasone 10 mg iv 30 minutes before each trabectedin infusion Patients may receive multiple cycles of trabectedin in the absence of disease progression

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
ET743-INT-3 None None None